LSH Silicone Hydrogel Soft Hydrophilic Contact Lens for Daily Wear

NCT ID: NCT01735045

Last Updated: 2012-11-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

76 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-05-31

Study Completion Date

2012-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is to evaluate the performance of the LSH (mangofilcon A) silicone hydrogel soft contact lenses when used as a daily wear contact lens for the correction of myopia.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myopia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Test Group myopia control

Subjects wearing contact lenses made of LSH (mangofilcon A) Soft (hydrophilic) Contact Lens for myopia control

Group Type EXPERIMENTAL

Lagado LSH (mangofilcon A) Soft (hydrophilic) Contact Lens

Intervention Type DEVICE

Daily Wear

Myopia Control

Subjects wearing Benz 3GX (hioxifilcon B) Soft (hydrophilic) Contact Lens for myopia control

Group Type ACTIVE_COMPARATOR

Benz 3GX (hioxifilcon B) Soft (hydrophilic) Contact Lens

Intervention Type DEVICE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lagado LSH (mangofilcon A) Soft (hydrophilic) Contact Lens

Daily Wear

Intervention Type DEVICE

Benz 3GX (hioxifilcon B) Soft (hydrophilic) Contact Lens

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Have been advised that the contact lenses they will be wearing for the next 3 months are being used for investigational purposes and that their informed consent will be needed and documented prior to the start of the study.
* Visual acuity must be correctable to 20/30, with spherical lenses ranging in power from -1.00 to -5.00D, astigmatism≤1.50D.
* Have been successfully wearing soft (hydrophilic) contact lenses for at least one month prior to entering the study. (Success means both subject and practitioner are satisfied with visual acuity, comfort, and ocular physiology).
* Have non-diseased eyes which are normal or which have no preexisting ocular condition which would interfere with the patient's ability to adapt to the new pair of LSH Silicone Hydrogel Soft (hydrophilic) Contact Lenses. A normal eye is defined as one having all the following characteristics:

1. No evidence of lid infection.
2. No structural lid abnormality.
3. No conjunctival abnormality or infection.
4. A cornea which is clear with no edema, staining, vascularization or abnormal opacities, all as observed by slit lamp examination.
5. No iritis.
6. No other active ocular disease that would contraindicate use of the investigational lens.
7. No GPC (giant papillary conjunctivitis, tarsal abnormality) Grade 2 or greater
* Use no ocular medication.
* Have no known sensitivity to solutions currently used for contact lens care.
* Have binocular correction with contact lenses.

Exclusion Criteria

* Astigmatism \>1.50D
* No monocular or monovision fits may be included.
* Pregnant and lactating women are excluded from the study
* Minors (under age 18) are excluded from the study
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Szabocsik and Associates, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

John M Szabocsik, PhD

Role: STUDY_DIRECTOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Glenda Secor, OD

Huntington Beach, California, United States

Site Status

Randall Sakamoto

Honolulu, Hawaii, United States

Site Status

Robert Davis, OD

Oak Lawn, Illinois, United States

Site Status

Douglas P. Benoit, OD, FAAO

Concord, New Hampshire, United States

Site Status

Stephen P. Byrnes, OD, FAAO

Londonderry, New Hampshire, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HF-2010-01

Identifier Type: -

Identifier Source: org_study_id